Journals / Retina-Vitreus / 2021 / Cilt: 30 - Sayı: 2

Comparison of Dose-Related Isotretinoin Effects on SD-OCT Parameters in Patients with Acne Vulgaris

Pages
146–151
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, it may be useful to monitor patients receiving high doses in clinical pra ctice with the SD-OCT.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To compare the effects of high- (Group 1) and low-dose (Group 2) systemic isotretinoin effects on spectral domain optic coherence tomography parameters in patients with acne vulgaris.
📊
Key Findings & Data:Material and methods: Thirty patients receiving high-dose (>0.5 mg/kg per day) systemic isotretinoin treatment and 32 patients treated with low-dose systemic isotretinoin (0.05).
💡
Conclusion & Impact:Therefore, it may be useful to monitor patients receiving high doses in clinical pra ctice with the SD-OCT.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To compare the effects of high- (Group 1) and low-dose (Group 2) systemic isotretinoin effects on spectral domain optic coherence tomography parameters in patients with acne vulgaris. Material and methods: Thirty patients receiving high-dose (>0.5 mg/kg per day) systemic isotretinoin treatment and 32 patients treated with low-dose systemic isotretinoin (0.05). But, at the fourth month visit, temporal and inferior quadrants of pRNFL in patients received high dose isotretinoinwere significantly lower than patients received low dose (p=0.037 and p=0.041, respectively). At the one month after the cessation of treatment, o nly temporal quadrant of pRNFL in Group 1 was signi ficantly lower than Group 2 (p=0.033). No statistically signi ficant difference was observed in other quadrants of pRNFL and mean pRNFL between two groups during the study. Conclusion: Low dose isotretinoin seems to have safety pro file for SFCT, mGCC and pRNFL. However, according to our results, high dose isotretinoin caused pRNFL thinning while caused no SFCT and mGCC thinning. High dose therapy may have a toxic effect on pRNFL, especially temporal and inferior quadrant. Therefore, it may be useful to monitor patients receiving high doses in clinical pra ctice with the SD-OCT.

🔖

Cite This Article

GÜNAY, Ü., TANYILDIZ, B., KANAR, H. S. (2022). Comparison of Dose-Related Isotretinoin Effects on SD-OCT Parameters in Patients with Acne Vulgaris. Retina-Vitreus, Cilt: 30 - Sayı: 2, 146–151. https://ajindex.com/articles/589052

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Tan, J.K.L. & Bhate, K. A global perspective on the epidemiology of acne. British Journal of Dermatology 172, 3-12 (2015)
  2. Barnes, L.E., Levender, M.M., Fleischer, A.B. & Feldman, S.R. Quality of Life Measures for Acne Patients. Dermatologic Clinics 30, 293-300 (2012)
  3. Dunn, L.K., O'Neill, J.L. & Feldman, S.R. Acne in adolescents: quality of life, self-esteem, mood, and psychological disorders. in Dermatol Online J, Vol. 17 1 (2011)
  4. Zaenglein, A.L., et al. Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology 74, 945-973.e933 (2016)
  5. Asai, Y., et al. Management of acne: Canadian clinical practice guideline. CMAJ 188, 118-26 (2016)
  6. Nast, A., et al. Methods report on the development of the European evidence-based (S3) guideline for the treatment of acne – update 2016. Journal of the European Academy of Dermatology and Venereology 30, e1-e28 (2016)
  7. Dawson, A.L. & Dellavalle, R.P. Acne vulgaris. BMJ: British Medical Journal 346, f2634 (2013)
  8. Amichai, B., Shemer, A. & Grunwald, M.H. Low-dose isotretinoin in the treatment of acne vulgaris. Journal of the American Academy of Dermatology 54, 644-6 (2006)
  9. Mandekou-Lefaki, I., Delli, F., Teknetzis, A., Euthimiadou, R. & Karakatsanis, G. Low-dose schema of isotretinoin in acne vulgaris. Int J Clin Pharmacol Res 23, 41-6 (2003)
  10. Ellis, C.N. & Krach, K.J. Uses and complications of isotretinoin therapy. Journal of the American Academy of Dermatology 45, S150-S157 (2001)
  11. Vallerand, I.A., et al. Ef ficacy and adverse events of oral isotretinoin for acne: a systematic review. British Journal of Dermatology 178, 76-85 (2018)
  12. Caglar, C., Senel, E., Sabancilar, E. & Durmus, M. Reduced ocular surface disease index (OSDI) scores in patients with isotretinoin treatment. International Ophthalmology 37, 197-202 (2017)
  13. Neudorfer, M., et al. Ocular Adverse Effects of Systemic Treatment With Isotretinoin. Archives of Dermatology 148, 803- 8 (2012)
  14. Citirik, M. & Tekin, K. Excessive serous retinal detachment during the use of isotretinoin. International Ophthalmology 38, 763-6 (2018)
  15. Santodomingo-Rubido, J., Barrado-Navascués, E. & Rubido- Crespo, M.-J. Drug-induced ocular side-effects with isotretinoin. Ophthalmic and Physiological Optics 28, 497-501 (2008)
  16. Tuğcu, B., Bitnel, M.K., Kaya, F.S., Güveli, B.T. & Ataklı, D. Evaluation of inner retinal layers with optic coherence tomography in vigabatrin-exposed patients. Neur